axSpA patients stayed longest on TNF inhibitor golimumab: Study

Adults with axial spondyloarthritis (axSpA) remained on golimumab longer than any other TNF inhibitor, according to a real-world analysis of medical records. Although adalimumab (marketed as Humira and biosimilars) was the most commonly prescribed first- and second-line TNF inhibitor, patients stayed with golimumab (marketed…

Bimekizumab shows benefits in treating axSpA at 1 year in trials

A year of treatment with bimekizumab was safe and significantly eased symptoms of axial spondyloarthritis (axSpA) in participants from two Phase 3 clinical trials, data show. “Results at [one year] from the BE MOBILE trials suggest that [bimekizumab] is an effective treatment option resulting in sustained efficacy across…

Restarting Taltz After Withdrawal Reduces axSpA Activity: Trial Data

Almost all people with axial spondyloarthritis (axSpA) who had worsening disease severity after stopping Taltz (ixekizumab) saw improvements after restarting the therapy, according to data from a Phase 3 withdrawal study. The majority (71%) reached a state of disease remission after restarting treatment. These findings provide important information about…